Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

被引：8
|
作者：
Kittai, Adam S. [1 ,4 ]
Best, Scott [1 ]
Thurlow, Bria [1 ]
Lam, Vi [1 ]
Hashiguchi, Taylor [1 ]
Goodyear, Shaun [1 ]
Persky, Daniel O. [2 ]
Okada, Craig [1 ]
Park, Byung [1 ]
Spurgeon, Stephen E. [1 ]
Danilov, Alexey V. [1 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA
[4] Ohio State Univ, Columbus, OH 43210 USA
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 07期
关键词：
INHIBITION; SYK; IBRUTINIB; GS-9973; MCL-1;
D O I：
10.3324/haematol.2020.270298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In recent years, the utilization of CS-MWCNT as targeted drug carriers has attracted considerable attention. Hericium erinaceus polysaccharide (HEP) has been reported as an immunostimulant to improve immune responses. This study was focussed on developing CS-MWCNT encapsulating HEP (CS-MWCNT-HEP). Using in mice peritoneal macrophages, we found the immune response could be effectively regulated by CS-MWCNT-HEP, promoted the expression of the MHCII, CD86, F4/80 and gp38. Moreover, the mice immunized with CS-MWCNT-HEP nanoparticles significantly extended PCV2-specific IgG immune response and the levels of cytokines. The results demonstrated that CS-MWCNT-HEP may be a promising drug delivery system for immuno-enhancement. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码：2022 / 2025
页数：4
相关论文
共 50 条
  • [31] Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kim, Haesook T.
    Savell, Alexandra
    Santiago-Medero, Carlos
    Francoeur, Karen
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [32] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [33] Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies
    Robak, Tadeusz
    Pluta, Agnieszka
    Robak, Pawel
    Janus, Agnieszka
    Wawrzyniak, Ewa
    Braun, Marcin
    LEUKEMIA & LYMPHOMA, 2025,
  • [34] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [35] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [36] Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
    Koenig, Kristin
    Dotson, Emily
    Sheredy, Shane
    Bhat, Seema A.
    Byrd, John C.
    Wiczer, Tracy
    Woyach, Jennifer
    Awan, Farrukh T.
    Rogers, Kerry A.
    BLOOD, 2019, 134
  • [37] HIGH-DOSE DEXAMETHASONE IN REFRACTORY B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA PATIENTS
    MOLICA, S
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (04) : 334 - 334
  • [38] Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Trelle, S
    Schnell, R
    Jensen, M
    Staib, P
    Schinköthe, T
    Stützer, H
    Rech, J
    Gramatzki, M
    Aulitzky, W
    Hasan, I
    Josting, A
    Hallek, M
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7024 - 7031
  • [39] Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: Updated data.
    Thieblemont, C
    Houot, R
    Toure, BA
    Traulle, C
    Michallet, AS
    Bouafia, F
    Espinouse, D
    Salles, G
    Coiffier, B
    BLOOD, 2005, 106 (11) : 340B - 340B
  • [40] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
12345